ZM-02-H

Phase 1Small molecule

ZZhongmou Therapeutics

ZM-02-H is one of 17 small molecule programs targeting Retinitis Pigmentosa. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinitis PigmentosaRecruiting

Retinitis PigmentosaPhase 1

Recruiting

Competition

Competitive Landscape

25 competitors in Retinitis Pigmentosa

#DrugCompanyPhaseTrials

Trexall

Plaquenil

Lodosyn

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—5

Bendopa

MMerz North America, Inc.

Approved

—6

Cysteine Hydrochloride

Novartis

Phase 3

1 7

Minocin

TTriax

Phase 3

2 8

Neoral

BS01

1 10

Human Retinal Progenitor Cells

JjCyte, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Retinitis Pigmentosa

NCT06292650

Clinical

Trials by Indication[1]

Retinitis Pigmentosa1 trial

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

Recruiting·ZZhongmou Therapeutics·Phase 1·NCT06292650·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ZM-02-H. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZM-02-H compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZM-02-H. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhongmou Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: ZZhongmou Therapeutics

ZM-02-H

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Retinitis Pigmentosa1 trial

References

Drug Info

Quick Facts

Related News